KDM6A and chronic myelomonocytic leukemia: Further studies are necessary to clarify how KDM6A recognizes inflammation‐related and aging‐related genes, and whether the inhibition of H3K27me3 may prevent leukemic transformation or offer potential therapeutic benefits for CMML.